What Is KINsight ?
KINsight is a prevention-led digital platform that enables low-friction early identification and ongoing management of inherited genetic cancer risk at population scale—before high-cost, late-stage disease emerges.
It combines structured family history analysis, clinically governed decision pathways, and long-term digital support to embed prevention within existing insurer and public-health ecosystems.
Why KINsight ?
KINsight is a prevention-led digital platform that enables low-friction early identification and ongoing management of inherited genetic cancer risk at population scale—before high-cost, late-stage disease emerges.
1 in 125
People Are Affected
Up to 80%
Face Repeat Cancers
50% of
Relatives May Carry It
90% of Carriers
Go Undiagnosed
What KINsight does
Around 10% of ALL cancers are caused by inherited genetic mutations (Inherited Genetic Causes of Cancer, IGCC).
Unlike lifestyle-driven cancers, IGCCs represent one of the few scalable levers available today: those at risk are identifiable, interventions are evidence-based, and early diagnosis is economically decisive.
Early Diagnosis
KINsight moves cancer care from late-stage treatment to identification, prevention, and early diagnosis to deliver a 5–10x cost-benefit ratio.
Prevention First
KINsight transforms inherited cancer from an unmanaged late-stage liability into a preventable, managed population-health opportunity.
Cost Savings
KINsight enables health systems, insurers, and employers to act on cancers they already expect to pay for, saving lives and costs.
Population-Scale Action
KINsight enables early identification and ongoing management of inherited genetic cancer risk at population scale, before high-cost, late-stage disease emerges.
Two Components Of KINsight
Genetic Family Tree
KINsight and Inherited Cancer Risk
Understand the key questions around inherited cancer risk, early identification, prevention, and how KINsight helps address them.
How common is inherited genetic cancer risk?
Inherited genetic mutations are responsible for around 10% of all cancers, and the three commonest inherited cancer risks affect about 1 in 125 people.
Why do so many inherited cancer carriers go undiagnosed?
Because carriers can only be confirmed through genetic testing, and population-wide testing is uneconomic, ethically complex, and operationally impractical.
Why is inherited cancer risk often missed until late?
These cancers often affect people in their 30s, 40s, and 50s, when symptoms may be dismissed, delaying diagnosis and increasing costs.
Why does inherited cancer risk matter for families?
Inherited cancer mutations run in families, and close relatives such as children, brothers, and sisters may also carry the same risk.
Can inherited cancer risk be reduced if identified early?
Yes. If carriers are identified early, evidence-based prevention, surveillance, and follow-up can reduce risk and support the earliest possible diagnosis.